Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
Neuropadiatrie, 1978/5;9(2):157-66.
Anders TF, Cann HM, Ciaranello RD, Barchas JD, Berger PA
PMID: 308621
Abstract
The effects of 5-hydroxytryptophan (5-HTP), a serotonin precursor, and carbidopa, a peripheral aromatic amino acid decarboxylase inhibitor, were studied in a boy with the Lesch-Nyhan syndrome. No effects on the self-mutilating behaviors of this disorder were noted. However, sleep patterns were normalized, with a reduction in the proportionate amounts of wakefulness and an augmentation of active sleep. A sharp reduction in waking behavioral dyskinesias was also correlated to increased drug dosage.
MeSH terms
5-Hydroxytryptophan; Carbidopa; Child; Drug Therapy, Combination; Humans; Hydrazines; Lesch-Nyhan Syndrome; Male; Movement Disorders; Self Mutilation; Sleep; Wakefulness
More resources
EndNote: Download